Literature DB >> 22234734

The role of serology in active ocular toxoplasmosis.

Marina Papadia1, Raffaella Aldigeri, Carl P Herbort.   

Abstract

Our purpose was to examine toxoplasmic serology in relation to episodes of suspected acute toxoplasmic retinochoroiditis and evaluate its use in the appraisal of patients. The mean values of enzymatic immunoassay (EIA) titers for toxoplasmic antibodies were retrospectively compared in patients with active and inactive toxoplasmosis and in a third group of uveitis cases not caused by toxoplasmosis. The proportion of cases under and above a predefined serology value above cut-off was compared in all groups. Between 1995 and 2010, 97 out of 1,276 new uveitis cases seen at the Centre for Ophthalmic Specialized Care (COS), Lausanne, Switzerland were diagnosed as toxoplasmic retinochoroiditis, of which 51 had documented serology available. The mean EIA values for immunoglobulin (Ig) G were 147.75 ± 259.4 IU/ml for patients with active disease, 18.93 ± 23.09 (p < 0.05) for patients with inactive toxoplasmosis and 18.35 ± 20.82 for controls (p < 0.017). The proportion of cases under the designated limit value were 2/51 (4%) in the active retinitinochoroiditis group, 14/27 (52%) (p < 0.05) in the control group, and 7/7 (100%) in the inactive toxoplasmic group (p < 0.001). Three out of 51 cases showed high IgM values in addition to IgG elevation and were primary infections. Toxoplasmosis serology, contrary to popular belief, is useful to confirm active toxoplasmic retinochoroiditis; it is easy to perform, cheap and supports clinical diagnosis in up to 96% of cases, not only by showing positivity but by also showing a significant elevation of titers. In atypical cases serology is not only useful but essential.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22234734     DOI: 10.1007/s10792-011-9507-z

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  8 in total

1.  Acquired toxoplasmic infection as the cause of toxoplasmic retinochoroiditis in families.

Authors:  C Silveira; R Belfort; M Burnier; R Nussenblatt
Journal:  Am J Ophthalmol       Date:  1988-09-15       Impact factor: 5.258

Review 2.  Reconsidering the pathogenesis of ocular toxoplasmosis.

Authors:  G N Holland
Journal:  Am J Ophthalmol       Date:  1999-10       Impact factor: 5.258

3.  Serologic evaluation of patients with primary and recurrent ocular toxoplasmosis for evidence of recent infection.

Authors:  J V Ongkosuwito; E H Bosch-Driessen; A Kijlstra; A Rothova
Journal:  Am J Ophthalmol       Date:  1999-10       Impact factor: 5.258

Review 4.  Toxoplasmosis.

Authors:  Adriana A Bonfioli; Fernando Orefice
Journal:  Semin Ophthalmol       Date:  2005 Jul-Sep       Impact factor: 1.975

5.  The importance of specific IgG and IgE autoantibodies to retinal S antigen, total serum IgE, and sCD23 levels in autoimmune and infectious uveitis.

Authors:  J C Muiño; C P Juárez; J D Luna; C C Castro; E G Wolff; M Ferrero; M D Romero-Piffiguer
Journal:  J Clin Immunol       Date:  1999-07       Impact factor: 8.317

6.  [Increase in polyclonal immunoglobulins: a possible useful aid in diagnosis of uveitis caused by sarcoidosis].

Authors:  J F Berthoud Kündig; A Keller; C P Herbort
Journal:  Klin Monbl Augenheilkd       Date:  1994-05       Impact factor: 0.700

Review 7.  Ocular toxoplasmosis: an update and review of the literature.

Authors:  Alessandra G Commodaro; Rubens N Belfort; Luiz Vicente Rizzo; Cristina Muccioli; Claudio Silveira; Miguel N Burnier; Rubens Belfort
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-03       Impact factor: 2.743

Review 8.  [Ocular toxoplasmosis].

Authors:  U Pleyer; N Torun; O Liesenfeld
Journal:  Ophthalmologe       Date:  2007-07       Impact factor: 1.174

  8 in total
  8 in total

1.  A 26-year-old man with a blind spot in his left eye.

Authors:  Alfred White; Timothy Saunders; Peter Pavan
Journal:  Digit J Ophthalmol       Date:  2013-09-25

Review 2.  Corticosteroids as adjuvant therapy for ocular toxoplasmosis.

Authors:  Smitha Jasper; Satyanarayana S Vedula; Sheeja S John; Saban Horo; Yasir J Sepah; Quan Dong Nguyen
Journal:  Cochrane Database Syst Rev       Date:  2017-01-26

3.  The impact of aqueous humor polymerase chain reaction and serological test results for establishing infectious uveitis diagnosis: An Indonesian experience.

Authors:  Ikhwanuliman Putera; Rina La Distia Nora; Nunik Utami; Anis Karuniawati; Andi Yasmon; Dewi Wulandari; Lukman Edwar; Made Susiyanti; Yulia Aziza; Priscilla Jessica; Mei Riasanti; Ratna Sitompul
Journal:  Heliyon       Date:  2022-10-08

Review 4.  Corticosteroids as adjuvant therapy for ocular toxoplasmosis.

Authors:  Smitha Jasper; Satyanarayana S Vedula; Sheeja S John; Saban Horo; Yasir J Sepah; Quan Dong Nguyen
Journal:  Cochrane Database Syst Rev       Date:  2013-04-30

5.  Seronegative ocular toxoplasma panuveitis in an immunocompetent patient.

Authors:  Monia Sigle; Wissam El Atrouni; Radwan S Ajlan
Journal:  Am J Ophthalmol Case Rep       Date:  2020-05-15

6.  Clinical and Biological Correlations in Toxoplasma gondii Infection in HIV Immune Suppressed Persons.

Authors:  Andrei Csep; Ligia Vaida; Simona Bungau; Bianca Ioana Todor
Journal:  Iran J Public Health       Date:  2015-07       Impact factor: 1.429

7.  Coinfections and differential diagnosis in immunocompetent patients with uveitis of infectious origin.

Authors:  Alejandra de-la-Torre; Juanita Valdés-Camacho; Clara López de Mesa; Andrés Uauy-Nazal; Juan David Zuluaga; Lina María Ramírez-Páez; Felipe Durán; Elizabeth Torres-Morales; Jessica Triviño; Mateo Murillo; Alba Cristina Peñaranda; Juan Carlos Sepúlveda-Arias; Jorge Enrique Gómez-Marín
Journal:  BMC Infect Dis       Date:  2019-01-25       Impact factor: 3.090

Review 8.  Ocular toxoplasmosis: a review of the current diagnostic and therapeutic approaches.

Authors:  Dimitrios Kalogeropoulos; Hercules Sakkas; Bashar Mohammed; Georgios Vartholomatos; Konstantinos Malamos; Sreekanth Sreekantam; Panagiotis Kanavaros; Chris Kalogeropoulos
Journal:  Int Ophthalmol       Date:  2021-08-09       Impact factor: 2.031

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.